Pharmaceutical Reactivation of Attenuated Apoptotic Pathways Leads to Elimination of Osimertinib Drug-Tolerant Cells

Osimertinib is an EGFR tyrosine kinase inhibitor (TKI) with proven clinical efficacy; however, acquired resistance presents an obstacle to curing EGFR-driven disease. Recent studies have shown that drug-tolerant persister cells (DTP) have a distinct transcriptional profile that may confer specific v...

Descripción completa

Detalles Bibliográficos
Autores principales: Martin, Matthew J., Floc'h, Nicolas, Pfeifer, Matthias, Criscione, Steven, Delpuech, Oona, Gagrica, Sladjana, Yao, Yi, McDermott, Ultan, Smith, Paul D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10035388/
https://www.ncbi.nlm.nih.gov/pubmed/36969743
http://dx.doi.org/10.1158/2767-9764.CRC-22-0066

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10035388/
https://www.ncbi.nlm.nih.gov/pubmed/36969743
http://dx.doi.org/10.1158/2767-9764.CRC-22-0066

Ejemplares similares